About
AYVAKYT

(avapritinib)

Indications1

Indolent Systemic Mastocytosis (ISM)

AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment

Advanced Systemic Mastocytosis (Advanced SM)

AYVAKYT® (avapritinib) is indicated as monotherapy for the treatment of adult patients with aggressive SM (ASM), SM with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy

AYVAKYT is a potent and highly selective inhibitor of KIT D816V1

Drawing of a clipboard with the AYVAKYT logo

Adapted from Gilreath JA, et al. 2019.4

Mechanism of disease

Both ISM2,3 and Advanced SM3,4 are driven by KIT D816V mutation in ~95% of cases

Targeted mechanism of action

  • AYVAKYT is a tyrosine kinase inhibitor that potently and selectively inhibits the autophosphorylation of KIT D816V, with an IC50 of 0.27 nM in in-vitro biochemical assays1,5
  • AYVAKYT inhibits constitutive KIT activation4
  • AYVAKYT inhibits mast cell proliferation and activation4
Illustration of AYVAKYT
Icon of a magnifying glass

Learn about the AYVAKYT key registration trials (PIONEER and PATHFINDER)

Clinical Trials

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the product SmPC for how to report adverse reactions.1

References

  1. AYVAKYT® (avapritinib). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Accessed September 2026.
  2. Muñoz-González JI, et al. Blood. 2019;134(5):456–468.
  3. Ungerstedt J, et al. Cancers. 2022;14(16):3942.
  4. Gilreath JA, et al. Clin Pharmacol. 2019;11:77−92.
  5. Evans EK, et al. Sci Transl Med. 2017;9(414):eaao1690.
To top